Stockscreener 앱 받기
0.7776
0.34%
0.0026
시간 외 거래:
.78
0.0024
+0.31%
Karyopharm Therapeutics Inc 주식(KPTI)의 최신 뉴스
Karyopharm appoints new chief accounting officer By Investing.com - Investing.com Canada
Karyopharm gains after changes to late-stage trial - MSN
Karyopharm appoints new chief accounting officer - Investing.com India
Karyopharm Therapeutics Appoints New Chief Accounting Officer - TipRanks
Karyopharm appoints Kristin Abate as Chief Accounting Officer - TipRanks
Karyopharm Therapeutics Inc. Appoints Kristin Abate as Chief Accounting Officer - Marketscreener.com
Karyopharm to Present Selinexor Data at the 66th American Society of Hematology Annual Meeting and Exposition - PR Newswire
Avidity Partners Management LP's Strategic Acquisition of Karyop - GuruFocus.com
Karyopharm Therapeutics' SWOT analysis: stock outlook amid pipeline progress By Investing.com - Investing.com Nigeria
Karyopharm Therapeutics' SWOT analysis: stock outlook amid pipeline progress - Investing.com India
Karyopharm Therapeutics (NASDAQ:KPTI) Stock Rating Upgraded by StockNews.com - MarketBeat
GSA Capital Partners LLP Purchases 792,283 Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) - MarketBeat
Leerink Partnrs Issues Optimistic Forecast for KPTI Earnings - MarketBeat
What is HC Wainwright's Estimate for KPTI FY2024 Earnings? - MarketBeat
Karyopharm Therapeutics Falls To US$0.88, But Insiders Sold At Lower Price - Simply Wall St
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock? - Yahoo Finance
Karyopharm Therapeutics (NASDAQ:KPTI) Stock Price Expected to Rise, Piper Sandler Analyst Says - Defense World
Karyopharm Therapeutics Reports Q3 2024 Financial Results and Corporate Progress - Defense World
Karyopharm Therapeutics Inc (KPTI) Is Worth Accumulating At Current Levels - Stocks Register
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q3 2024 Earnings Call Transcript - Insider Monkey
Karyopharm stock price target raised, overweight on revenue beat - Investing.com India
Karyopharm therapeutics CEO Richard Paulson sells $3,346 in stock - Investing.com
Karyopharm therapeutics CEO Richard Paulson sells $3,346 in stock By Investing.com - Investing.com Canada
Karyopharm stock price target raised, overweight on revenue beat By Investing.com - Investing.com Australia
Earnings call: Karyopharm Therapeutics reports on clinical and financial progress - Investing.com Nigeria
Piper Sandler Boosts Karyopharm Therapeutics (NASDAQ:KPTI) Price Target to $5.00 - MarketBeat
Karyopharm price target raised to $5 from $4 at Piper Sandler - TipRanks
Karyopharm Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Karyopharm Therapeutics Inc (KPTI) Q3 2024 Earnings Call Highlig - GuruFocus.com
Karyopharm Therapeutics' SWOT analysis: oncology firm's stock faces pivotal year - Investing.com Australia
Karyopharm Therapeutics Inc (KPTI) Q3 2024 Earnings Call Highlights: Navigating Growth Amidst ... - Yahoo Finance
Karyopharm Therapeutics Inc. Reports Q3 2024 Earnings - TipRanks
Karyopharm Therapeutics Q3 2024 Earnings Preview - MSN
Karyopharm Therapeutics (KPTI) Q3 2024 Earnings Call Transcript - AOL
Karyopharm Therapeutics: Q3 Earnings Snapshot - San Francisco Chronicle
Karyopharm Therapeutics (KPTI) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Karyopharm Therapeutics Inc (KPTI) Q3 2024 Earnings: EPS Loss of - GuruFocus.com
Karyopharm Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Karyopharm Reports Third Quarter 2024 Financial Results and Highlights Recent Company Progress - PR Newswire
Karyopharm Therapeutics Inc (KPTI) Q3 2024: Everything You Need To Know Ahead Of Earnings - GuruFocus.com
KPTIKaryopharm Therapeutics Inc. Latest Stock News & Market Updates - StockTitan
Karyopharm Therapeutics (KPTI) May Report Negative Earnings: Know the Trend Ahead of Q3 Release - MSN
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - WV News
Karyopharm Therapeutics (KPTI) to Release Quarterly Earnings on Tuesday - MarketBeat
Karyopharm Therapeutics' (KPTI) Buy Rating Reiterated at HC Wainwright - MarketBeat
Karyopharm updates SENTRY trial endpoints, eyes 2025 data - Investing.com India
Karyopharm updates SENTRY trial endpoints, eyes 2025 data By Investing.com - Investing.com Canada
0.93%
3.55%
자본화:
|
볼륨(24시간):